Real-World Data Offering from Proscia: Empowering Life Sciences to Advance Precision Medicine Pipelines

PathAI: Latest research underscores advantages of digital tools at scale to enhance tumor microenvironment and biomarker understanding in non-small cell lung cancer and renal cell carcinoma BOSTON, Mass., April 11, 2023 /PRNewswire/...

Houston is one of seven global Precision specialty labs addressing the rising demand for rapid, comprehensive biomarker data to support the development of advanced therapies and diagnostics HOUSTON, April 11, 2023 /PRNewswire/ -- Precision...

Invitation from Deep Bio: Our team is ready to greet you at booth #3445! Find out how DeepDx® Prostate empowers pathologists. Also, Deep Bio will present two research abstracts in relation to biomarker in prostate and breast cancers at...

PathAI PathExplore™ panel will empower oncology drug developers with improved tumor microenvironment spatial characterization from H&E, propelling a new phase of precision medicine. BOSTON, April 4, 2023 /PRNewswire/ -- PathAI, a...

Nijmegen, Netherlands – Aiosyn, a medical software company that develops AI-powered pathology solutions, has been awarded a 1,6M € Eurostars grant together with Pathomation and Radboud University Medical Center to accelerate the development...

TOKYO, (April 03, 2023)— Evident Corporation (“Evident”) announced today that it has been acquired by private equity firm Bain Capital Private Equity (“Bain Capital”) from Olympus Corporation (“Olympus”) pursuant to the definitive...